[Results of fraxiparin and ticlid therapy of acute retinal vessels occlusion].
Out of 78 patients with occlusive processes in retinal vessels aged 22-78 years, 28 were treated by combined therapy including heparin (group 1, controls) and for the rest 54 (test group) heparin was replaced by fraxiparin. Fraxiparin is a low-molecular heparin administered parabulbarly in a dose of 0.07 ml with 0.03 ml isotonic sodium chloride. Forty-two out of 54 patients in the test group were administered ticlopedin (ticlide), a disaggregant, in a daily dose of 250 mg (1 tablet) for 1 month; blood aggregation and lacrimal fluid coagulation and fibrinolytic activities were monitored over the course of treatment. Fraxiparin sooner improved visual acuity and caused a lesser number of side effects: in group 1 visual acuity improved in 45.8% and did not change or deteriorated in 54.2%, whereas in the fraxiparin group these values were 68.58 and 31.42%, respectively. Ticlide decreased the risk of repeated occlusions, which occurred in 4 patients vs. 11 in the control group, including those presenting as myocardial infarctions and brain strokes.